Last Price$222.71.6%
Market Cap$21.9B
LTM Research & Development Expenses (R&D)
$107.4M
YoY Growth
+2.5%
3Y CAGR
+10.6%
5Y CAGR
+10.8%
Stock quality & Intrinsic value
6/10
10.4% overvalued
STERIS plc Research & Development Expenses (R&D)
Annual
Quarterly
LTM
Crunching data... Almost there!
| Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | Mar'12 | Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & Development Expenses (R&D) | $35.5M | $33.6M | $33.6M | $36.9M | $32.8M | $34.0M | $34.3M | $36.0M | $41.3M | $48.6M | $54.1M | $56.7M | $59.4M | $60.8M | $63.0M | $65.5M | $66.3M | $87.9M | $101.6M | $103.7M |
Overvalued or undervalued?
Check the intrinsic value for STE
and see if it's the right time to invest.
STERIS plc (STE) Research & Development Expenses (R&D) comparison analysis
General
LTM Research & Development Expenses (R&D)
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
STERIS plcSTE
$107.4M
2.5%
10.6%
10.8%
Median Peer Set
$1,268.1M
4.7%
3.4%
7.5%
Abbott LaboratoriesABT
$2,839.0M
4.0%
1.2%
3.1%
Medtronic plcMDT
$2,723.0M
0.8%
(0.0%)
2.9%
Koninklijke Philips N.V.PHG
$1,891.0M
(7.5%)
(1.1%)
(1.5%)
Boston Scientific CorporationBSX
$1,615.0M
14.1%
10.3%
6.6%
Stryker CorporationSYK
$1,455.0M
4.8%
5.6%
8.4%
Edwards Lifesciences CorporationEW
$1,081.2M
4.6%
7.7%
8.4%
DexCom, Inc.DXCM
$552.4M
9.2%
(2.9%)
15.1%
Align Technology, Inc.ALGN
$364.2M
5.0%
13.3%
18.3%
Zimmer Biomet Holdings, Inc.ZBH
$328.9M
(28.3%)
(11.8%)
(6.0%)
Insulet CorporationPODD
$219.6M
7.1%
11.1%
11.1%
STE key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | Mar'12 | Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 1,119.7 3.0% | 1,160.3 3.6% | 1,197.4 3.2% | 1,265.1 5.7% | 1,298.5 2.6% | 1,257.7 (3.1%) | 1,207.4 (4.0%) | 1,391.5 15.2% | 1,501.9 7.9% | 1,622.3 8.0% | 1,850.3 14.1% | 2,238.8 21.0% | 2,612.8 16.7% | 2,620.0 0.3% | 2,782.2 6.2% | 3,030.9 8.9% | 3,107.5 2.5% | 4,585.1 47.5% | 4,957.8 8.1% | 5,138.7 3.6% |
| Cost of Goods Sold (COGS) | 648.1 | 676.1 | 692.6 | 741.1 | 771.8 | 718.6 | 761.3 | 823.0 | 880.6 | 972.6 | 1,076.0 | 1,343.3 | 1,587.1 | 1,525.8 | 1,606.7 | 1,711.0 | 1,764.4 | 2,568.7 | 2,798.1 | 2,920.5 |
% margin | 471.7 42.1% | 484.2 41.7% | 504.8 42.2% | 524.0 41.4% | 526.7 40.6% | 539.2 42.9% | 446.2 37.0% | 568.5 40.9% | 621.3 41.4% | 649.6 40.0% | 774.3 41.8% | 895.5 40.0% | 1,025.6 39.3% | 1,094.2 41.8% | 1,175.4 42.2% | 1,319.9 43.5% | 1,343.1 43.2% | 2,016.4 44.0% | 2,159.7 43.6% | 2,218.2 43.2% |
| Operating Expenses | 326.7 | 349.2 | 360.5 | 385.0 | 347.7 | 330.6 | 359.7 | 345.5 | 395.8 | 429.6 | 547.5 | 683.4 | 739.5 | 690.7 | 733.0 | 782.3 | 797.6 | 1,590.7 | 1,400.5 | 1,382.0 |
| Research & Development Expenses (R&D) | 35.5 | 33.6 | 33.6 | 36.9 | 32.8 | 34.0 | 34.3 | 36.0 | 41.3 | 48.6 | 54.1 | 56.7 | 59.4 | 60.8 | 63.0 | 65.5 | 66.3 | 87.9 | 101.6 | 103.7 |
| Selling, General & Administrative Expenses (SG&A) | 291.1 | 315.6 | 326.9 | 348.0 | 315.0 | 296.6 | 325.5 | 309.6 | 354.5 | 381.0 | 493.3 | 626.7 | 680.1 | 629.9 | 669.9 | 716.7 | 731.3 | 1,502.8 | 1,298.9 | 1,252.3 |
% margin | 145.0 12.9% | 109.7 9.5% | 137.7 11.5% | 123.5 9.8% | 175.4 13.5% | 203.7 16.2% | 85.2 7.1% | 222.3 16.0% | 242.8 16.2% | 206.8 12.7% | 227.2 12.3% | 212.9 9.5% | 227.6 8.7% | 403.5 15.4% | 411.5 14.8% | 341.1 11.3% | 323.3 10.4% | 425.6 9.3% | 268.2 5.4% | 836.1 16.3% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 1.6 | 1.3 | 0.6 | 0.9 | 0.0 | 0.3 | 0.8 | 1.7 | 1.6 | 2.2 | 3.0 | 2.0 | 6.3 | 6.3 | 108.0 | 11.0 |
| Interest Expense | 3.1 | 44.9 | 16.9 | 34.7 | 10.6 | 13.2 | 12.0 | 12.1 | 15.7 | 18.8 | 19.2 | 42.7 | 44.5 | 50.6 | 45.0 | 40.3 | 37.2 | 89.6 | 109.6 | 144.4 |
| Pre-tax Income | 141.9 | 108.1 | 132.9 | 119.8 | 166.5 | 191.8 | 73.8 | 211.1 | 227.1 | 188.4 | 208.8 | 171.9 | 184.6 | 355.0 | 369.5 | 498.7 | 517.5 | 314.5 | 157.3 | 702.8 |
% effective tax rate | 56.0 39.4% | 45.2 41.8% | 51.8 39.0% | 42.7 35.6% | 55.8 33.5% | 63.3 33.0% | 22.6 30.6% | 75.0 35.5% | 67.1 29.6% | 58.9 31.3% | 73.8 35.3% | 60.3 35.1% | 74.0 40.1% | 63.4 17.8% | 64.4 17.4% | 90.9 18.2% | 120.7 23.3% | 71.6 22.8% | 51.5 32.8% | 149.5 21.3% |
% margin | 86.0 7.7% | 70.3 6.1% | 82.2 6.9% | 77.1 6.1% | 110.7 8.5% | 128.5 10.2% | 51.3 4.2% | 136.1 9.8% | 160.0 10.7% | 129.4 8.0% | 135.1 7.3% | 110.8 4.9% | 110.0 4.2% | 290.9 11.1% | 304.1 10.9% | 407.7 13.5% | 397.4 12.8% | 243.9 5.3% | 107.0 2.2% | 378.2 7.4% |
| EPS | 1.24 | 1.03 | 1.26 | 1.22 | 1.88 | 2.18 | 0.86 | 2.33 | 2.74 | 2.20 | 2.27 | 1.57 | 1.29 | 3.42 | 3.59 | 4.81 | 4.66 | 2.50 | 1.07 | 3.83 |
| Diluted EPS | 1.23 | 1.02 | 1.25 | 1.20 | 1.86 | 2.16 | 0.85 | 2.31 | 2.72 | 2.17 | 2.25 | 1.56 | 1.28 | 3.39 | 3.56 | 4.76 | 4.63 | 2.48 | 1.07 | 3.81 |
% margin | 196.2 17.5% | 171.0 14.7% | 200.4 16.7% | 188.6 14.9% | 235.8 18.2% | 261.2 20.8% | 140.4 11.6% | 286.1 20.6% | 294.5 19.6% | 303.8 18.7% | 319.5 17.3% | 438.7 19.6% | 503.0 19.3% | 594.5 22.7% | 693.1 24.9% | 743.2 24.5% | 800.3 25.8% | 957.2 20.9% | 1,344.0 27.1% | 1,412.4 27.5% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is STERIS plc's Research & Development Expenses (R&D)?
As of today, STERIS plc's last 12-month Research & Development Expenses (R&D) is $107.4M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is STERIS plc's Research & Development Expenses (R&D) growth rate?
Over the last year, STERIS plc's Research & Development Expenses (R&D) growth was 2.5%. The average annual Research & Development Expenses (R&D) growth rates for STERIS plc have been 16.3% over the past three years, 10.8% over the past five years.
3) Is STERIS plc's Research & Development Expenses (R&D) growth rate Good?
Over the last year, STERIS plc's Research & Development Expenses (R&D) growth was 2.5%, which is higher than industry growth of (0.0%). It indicates that STERIS plc's Research & Development Expenses (R&D) growth is Bad.